Page last updated: 2024-11-13

brevianamide a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

brevianamide B: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

brevianamide A: metabolite of Penicillium viridicatum; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25163935
MeSH IDM0049557
PubMed CID46914544
MeSH IDM0049557

Synonyms (21)

Synonym
nsc-208423
23402-09-7
(-)-brevianamide a
l2s5e3nbih ,
spiro(5h,6h-5a,9a-(iminomethano)-1h-cyclopent(f)indolizine-7(8h),2'-(2h)indole)-3',5,10(1'h)-trione, 2,3,8a,9-tetrahydro-8,8-dimethyl- (van)
unii-l2s5e3nbih
nsc 208423
brevianamide b
spiro(5h,6h-5a,9a-(iminomethano)-1h-cyclopent(f)indolizine-7(8h),2'-indoline)-3',5,10-trione, 2,3,8a,9-tetrahydro-8,8-dimethyl-
(+)-brevianamide a
brevianamid a
(2'r,5ar,8as,9ar)-2,3,8a,9-tetrahydro-8,8-dimethylspiro(5h,6h-5a,9a-(iminomethano)-1h-cyclopent(f)indolizine-7(8h),2'-(2h)indole)-3',5,10(1'h)-trione
brevianamide a, (+)-
spiro(5h,6h-5a,9a-(iminomethano)-1h-cyclopent(f)indolizine-7(8h),2'-(2h)indole)-3',5,10(1'h)-trione, 2,3,8a,9-tetrahydro-8,8-dimethyl-, (2'r,5ar,8as,9ar)-
(1r,3s,5r,7r)-4,4-dimethyl-13h-spiro[9,14-diazatetracyclo[5.5.2.01,9.03,7]tetradecane-5,2'-indole]-3',8,13(1'h)-trione
DTXSID90891803
Q63409794
nsc784315
nsc-784315
(1'r,2r,7'r,9's)-10',10'-dimethylspiro[1h-indole-2,11'-3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane]-2',3,14'-trione
brevianamide a

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" This study examined dose-response (0."( Inflammatory and cytotoxic responses in mouse lungs exposed to purified toxins from building isolated Penicillium brevicompactum Dierckx and P. chrysogenum Thom.
Flemming, J; Giles, S; Miller, JD; Puniani, E; Rand, TG, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.14)18.7374
1990's2 (14.29)18.2507
2000's3 (21.43)29.6817
2010's6 (42.86)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.31 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Reviews2 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
Other8 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]